Please login to the form below

Not currently logged in
Email:
Password:

V Bryan Lawlis joins board of KaloBios

Is co-founder of Itero and Covance

KaloBios has announced that Dr V Bryan Lawlis is to join the company's board of directors.

Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.

He has entrepreneurial experience, co-founding Itero in 2006 and contract manufacturing firm Covance Biotechnology Services in 1996.

Other previous roles include CEO of Aradigm Corporation, VP of process sciences at Genetech.

His extensive industry knowledge and drug development experience, especially in the manufacturing of therapeutic proteins and antibodies, will serve KaloBios well as we advance the development of our portfolio of proprietary, patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios.

This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.

9th August 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mind+Matter

We are Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for our...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...